Evidence map›Paper›PMID 40376585›Full record

ArticleFrontiers in oncology2025

Artificial intelligence in automatic image segmentation system for exploring recurrence patterns in small cell carcinoma of the lung.

Jing Shen, Shaobin Wang, Hui Guan, Mingyi Di, Zhikai Liu, Qi Chen, Mei Li, Jie Shen, Ke Hu, Fuquan Zhang

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jing Shen *Department of Radiation Oncology, Peking Union Medical College, Beijing, China.
Shaobin Wang *Product Development Department, MedMind Technology Co, Ltd., Beijing, China.
Hui GuanDepartment of Radiation Oncology, Peking Union Medical College, Beijing, China.
Mingyi DiDepartment of Radiation Oncology, Peking Union Medical College, Beijing, China.
Zhikai LiuDepartment of Radiation Oncology, Peking Union Medical College, Beijing, China.
Qi ChenProduct Development Department, MedMind Technology Co, Ltd., Beijing, China.
Mei LiDepartment of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China.
Jie ShenDepartment of Radiation Oncology, Peking Union Medical College, Beijing, China.
Ke HuDepartment of Radiation Oncology, Peking Union Medical College, Beijing, China.
Fuquan ZhangDepartment of Radiation Oncology, Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The integration of artificial intelligence (AI) in automatic image segmentation systems offers a novel approach to evaluating the clinical target volume (CTV) in small cell lung cancer (SCLC) patients. Utilizing imaging recurrence data, this study applies a recursive feature elimination algorithm to model and predict patient prognoses, aiming to enhance clinical guidance and prediction accuracy. Materials and Methods: This research analyzed data from SCLC patients who received curative radiotherapy from January 1, 2010, to December 30, 2021, and had comprehensive follow-up records including pre- and post-treatment imaging. An AI-driven image segmentation system segmented the initial CTV, evaluating 110 clinical parameters. The recursive feature elimination method selected pertinent features, and a random forest-based recursive prediction model was developed to establish a clinically viable recurrence prediction model. Results: 1. Local Control Analysis: A study of 180 patients, with a median follow-up duration of 36 months, revealed that 94 experienced recurrences, while 86 did not. Factors influencing local control rates included gender (male), age (>60 years), T stage, smoking index, and tumor size. Notably, tumor size (≥ 5cm) emerged as an independent factor significantly impacting local control rates, with a Hazard Ratio (HR) of 1.635 (95% CI: 1.055-2.536, p=0.028). 2. Recurrence Analysis: Tumor size (≥ 5cm) was also closely linked to patient local control rates, with a 3-year Local Control Rate Failure (LCRF) contrasting sharply between larger tumors (61.1%) and smaller tumors (86.7%, p=0.004). Upon analyzing recurrence patterns among 94 patients, a total of 170 instances were examined. Recurrence was most prevalent in regions 10R, 10L, 4R, and 7, accounting for 67.65% (115/170) of cases, while regions 2L and 3P showed no recurrences. The initial region of the primary tumor or metastatic lymph nodes was identified as a critical recurrence area, with a 100% recurrence rate in patients whose initial tumor region included 10 specific regions. The recurrence rates for initial tumor regions involving 4R, 7, 11R, and 11L ranged between 41.6% and 45.5%. 3. Development of a recurrence prediction model: utilizing an AI-powered automatic image segmentation system, multidimensional partition parameters, including 110 clinical variables, were analyzed. The recursive feature elimination method facilitated efficient feature selection. From this, a recurrence prediction model for small cell lung cancer was developed using a random forest algorithm, achieving a clinically significant accuracy rate of 77%. This model provides a reliable basis for enhancing the clinical application and decision-making process for medical practitioners. Conclusion: The utilization of AI-based automatic image segmentation system for delineating the initial CTV has proven pivotal. Analysis and modeling of recurrent images reveal that the initial GTV and GTVnd are critical regions for recurrence. Leveraging partition parameter and variable information, we constructed a clinically viable recurrence prediction model. This model significantly aids in guiding the precise clinical targeting of treatment areas, demonstrating the potential of AI to enhance patient management and treatment outcomes in small cell lung cancer.

Indexed as

artificial intelligenceclinical target volume (CTV)local recurrenceprediction modelsmall cell lung cancer

Identifiers

PMID40376585
PMCPMC12078232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.